ABSTRACT
Background: Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid peptide (Aβ) in terms of synthesis, clearance or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ 1-42 is evident in AD, and the CSF ratio Aβ 40 /Aβ 40 has recently been identified as one of the most reliable diagnostic biomarkers of amyloid pathology. Variations in inter-individual levels of Aβ 1-40 in the CSF have been observed in the past, but their origins remain unclear. In addition, the variation of Aβ 40 in the context of AD studied in several studies has yielded conflicting results.
Methods Here, we analyzed the levels of Aβ 1-40 using multicenter data obtained on 2466 samples from six different cohorts in which CSF was collected under standardized protocols, centrifugation and storage conditions. Tau and p-tau(181) concentrations were measured using commercially available in vitro diagnostic immunoassays. Concentrations of CSF Aβ 1-42 and Aβ 1-40 were measured by ELISA, xMAP technology, chemiluminescence immunoassay (CLIA) and mass spectrometry. Statistical analyses were calculated for parametric and non-parametric comparisons, linear regression, correlation and odds ratios. The statistical tests were adjusted for the effects of covariates (age, in particular).
Results: Regardless of the analysis method used and the cohorts, a slight but significant age-independent increase in the levels of Aβ 40 in CSF was observed in AD. We also found a strong positive correlation between the levels of Aβ 40 and p-tau(181) in CSF, particularly in control patients.
Conclusions: These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau(181), may be a biological characteristic of AD. This confirms the potential therapeutic value of lowering the baseline levels of Aβ 40 which, being elevated, can be considered a risk factor for the disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is a multi-centre retrospective cohort study with no patient intervention. It has been authorized at the ethical and regulatory level (see text) but did not require clinical trial registration.
Funding Statement
This work was supported by "France Alzheimer" and via the French National Alzheimer effort ("Le Plan Alzheimer"). Data collection and sharing for this project was also funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used for the analyses are available from the corresponding author on reasonable request.
Abbreviations
- AD
- Alzheimer’s disease
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative
- APP
- amyloid precursor protein
- AUC
- Area under the curve; Aβ: Amyloid β
- CAA
- cerebral amyloid angiopathy
- CI
- Confidence interval
- CLIA
- chemiluminescence immunoassay
- CMRR
- Centre Mémoire de Ressources et de Recherche
- CSF
- Cerebrospinal fluid
- FTD
- Frontotemporal degeneration
- FTLD
- Frontotemporal lobar degeneration
- LBD
- Lewy Body dementia
- MCI
- Mild cognitive impairment
- MMSE
- Mini Mental State Examination
- MRI
- magnetic-resonance brain imaging
- NAD
- Non Alzheimer disease
- NFT
- neurofibrillary tangles
- PET
- Positron-Emission Tomography; PiB: Pittsburgh compound B
- PLM
- Paris-Lille-Montpellier
- PSP
- Progressive Supra-nuclear Palsy
- QC
- Quality control
- ROC
- Receiver operating characteristic
- SD
- Standard deviation.